PubMed Health⌕ Search

PubMed · 8914001

Hepatitis B virus replication--an update.

Abstract

Hepatitis B virus (HBV), the causative agent of type B hepatitis in humans, is the prototypic member of the hepadnaviridae, a family of small enveloped DNA-containing viruses with pronounced host and tissue specificity. This property has greatly hampered progress in understanding the initial events of infection, i.e. attachment, penetration and uncoating. After the discovery, originally made with the duck hepatitis B virus (DHBV), that hepadnaviruses replicate by reverse transcription, DNA transfection of cloned wild-type and mutant HBV genomes into cell lines supporting virion formation has revealed the molecular mechanisms of the late steps of the infectious cycle in some detail. During the last few years, such studies have emphasized the differences between hepadnaviral and retroviral replication. Very recent research, however, indicates that the border separating the two viral families may not be as strict as previously thought. In this article, we will briefly summarize the pertinent differences, and will then focus on the new data, with particular emphasis on the initiation of reverse transcription.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Nassal, H Schaller. 1996. Hepatitis B virus replication--an update.. https://doi.org/10.1111/j.1365-2893.1996.tb00047.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

[Study of gene chips in the detection of YMDD mutations in the region of HBV polymeras].

OBJECTIVE: To understand mutations of the HBV polymerase from the level of molecule-biology and to guide reasonably antiviral therapy in clinic and predict prognosis of the patients, the gene chips were applied to detect YMDD mutations for the serum samples with HBV DNA position before antiviral therapy. METHODS: The serum samples from 150 HBV DNA positive patients non-antiviral therapy were detected by nowly advanced gene chip technique for YMDD wildtype and YVDD and/or YIDD mutations in the region of HBV polymerase. Several positive samples had been testified by gene sequences. RESULTS: Out of 150 serum samples of HBVDNA position patients tested by gene chips, 122 cases (including YMDD wildtype and mutations) were positive (81.3%), 28 cases were negative (18.7%). In 122 positive samples, 90 cases were YMDD wildtype (73.8%) (non-mutations), 28 cases were YVDD mutation (22.9%), 2 cases were YIDD mutation (1.6%), 2 cases were YVDD/YIDD double mutations (1.6%). Total mutation rate is 26.2%. Sequence analysis of 8 positive samples verified that gene chips were available. CONCLUSION: (1) Gene chip technique for the detection of mutations of the YMDD in the region of the HBV polymerase is reliable and its specificity is high. (2) Gene chips can simultaneously and quickly detect HBV YMDD wildtype and YVDD, YIDD mutations. (3) HBV YMDD mutations have existed in several patients HBV DNA position before antiviral therapy and YVDD mutation is high. YMDD wildtype and mutation strain coexist. (4) To guide reasonably antiviral therapy in clinic and make therapeutic remedy, it is necessary for HBV-infected patients before or after antiviral therapy to detect HBV YMDD mutations.

Gene Products, pol↗

The newly synthetized pyridobenzoxazocynone inhibits HIV-1 reverse transcriptase activity.

We synthetized pyridobenzoxazocynone that differs in the enlarged eight-membered heterocyclic system from the basic structure of pyridobenzoxazepinones a known class of non-nucleoside HIV-1 reverse transcriptase inhibitors. Pyridobenzoxazocynone hydrochloride was found to inhibit HIV-1 reverse transcriptase activity. At concentration 0.35 microM the enzyme activity decreased by 64 +/- 14%. Higher concentrations of pyridobenzoxazocynone hydrochloride completely abolished the enzyme activity expressed as radioactivity of acid insoluble products. These results suggest that pyridobenzoxazocynones may represent a new class of HIV-1 reverse transcriptase inhibitors.

Gene Products, pol↗